Jupiter Asset Management
NTLA icon

Jupiter Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Jupiter Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$19.8M Sell
1,640,962
-208,545
-11% -$2.61M 0.09% 232
2026
Q2 		$31.3M Buy
1,849,507
+68,444
+4% +$958K 0.16% 164
2026
Q1 		$22.8M Buy
1,781,063
+743,145
+72% +$9.47M 0.12% 199
2025
Q4 		$9.33M Sell
1,037,918
-323,931
-24% -$4.46M 0.07% 222
2025
Q3 		$23.5M Buy
+1,361,849
New +$16.8M 0.2% 143

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Tarrytown, New York $180M AUM 18.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Contrarius Group Holdings
Contrarius Group Holdings Hamilton, Bermuda $2.05B AUM 66.09% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Pinnacle Associates
Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Jupiter Asset Management's NTLA Position: Q3 2026 in Review

Jupiter Asset Management reduced its Intellia Therapeutics (NTLA) stake by 11% in Q3 2026, selling an estimated $2.61M and leaving 1,640,962 shares worth $19.8M. The position accounts for 0.09% of the portfolio, ranked #232.

Jupiter Asset Management first reported a position in NTLA in Q3 2025 and has held it in 5 quarters since. The position peaked at $31.3M in Q2 2026. 147 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

  • Jupiter Asset Management held 1,640,962 shares of Intellia Therapeutics worth $19.8M as of Q3 2026.
  • Jupiter Asset Management sold 208,545 Intellia Therapeutics shares in Q3 2026, an estimated $2.61M.
  • Intellia Therapeutics made up 0.09% of Jupiter Asset Management's portfolio in Q3 2026, its #232 holding.
  • Jupiter Asset Management first reported a position in Intellia Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • Jupiter Asset Management's Intellia Therapeutics position peaked at $31.3M in Q2 2026.
  • 147 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on Jupiter Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.